Clinical Trial Update: Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating PCSK9 inhibition on arterial wall inflammation in patients with elevated Lp(a); study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hyperlipidemia

Drugs mentioned

• PCSK9 inhibitor (PCSK9 inhibitor)

Snippet

Sponsor: Amgen | Conditions: Subjects With Hyperlipidemia, Dyslipidemia | Phase 3 | Status: COMPLETED | Results posted: 2019-04-23